Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown Human Papillomavirus (HPV) Detection by HPV Genotype
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in HPV-based cervical screening. The main questions it aims to answer are:
- Whether an incident HPV detection with certain HPV genotypes has low risk of cervical cancer in 3 to 5 years thus does not need further clinical assessment before the next screening test?
- How risky a persistent HPV detection is, and whether persistent detection of any high-risk HPV genotype warrant immediate clinical assessment?
- How risky a HPV detection is, if no previous HPV test result is available?
As being a register-based retrospective observational study, study subjects will not be asked to do any specific task for this study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study includes all women in the study population (women at screening ages and living in the Stockholm region during 2014-2023) who had HPV positive test result(s) in the primary HPV screening. In 2014-2016, half of the screening population were randomised to primary HPV screening and the other half received cytology-based screening (NCT01511328). From 2017 onwards, all women received primary HPV screening. As data are retrieved from established registries which are already accessible to the researchers for previous and ongoing related research projects, the data collection time is almost negligible.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jiangrong Wang, PhD
- Phone Number: +46769309451
- Email: jiangrong.wang@ki.se
Study Contact Backup
- Name: Joakim Dillner, PhD
- Email: joakim.dillner@ki.se
Study Locations
-
-
-
Stockholm, Sweden, 141 52
- Recruiting
- Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
-
Contact:
- Jiangrong Wang, PhD
- Phone Number: +46769309451
- Email: jiangrong.wang@ki.se
-
Contact:
- Email: jiangrong.wang@ki.se
-
Sub-Investigator:
- Jiangrong Wang, PhD
-
Principal Investigator:
- Joakim Dillner, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in the primary HPV test during 2014-2023
Description
Inclusion Criteria:
- Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in primary HPV test during 2014-2023
Exclusion Criteria:
- Women without valid personal identity number in the population registry
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Incident HPV detection
The first HPV positive result in the primary HPV test, following an HPV negative test result in the previous primary HPV test |
All data will be retrieved retrospectively from registry data. |
|
Persistent HPV detection
The HPV positive result in the primary HPV test following an HPV positive test result with the same genotype in the previous primary HPV test |
All data will be retrieved retrospectively from registry data. |
|
History-unknown HPV detection
The first HPV positive result in the primary HPV test, without any primary HPV test record in the past |
All data will be retrieved retrospectively from registry data. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnosis of invasive cervical cancer
Time Frame: From HPV infection to the end of the study Dec 31st, 2024
|
Primary and invasive cervical cancer |
From HPV infection to the end of the study Dec 31st, 2024
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Precancerous lesion CIN2+ (Cervical Intraepithelial Neoplasia grade 2 and above)
Time Frame: From HPV infection to the end of the study Dec 31st, 2024
|
CIN2, CIN3, Adenocarcinoma in situ |
From HPV infection to the end of the study Dec 31st, 2024
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Bjorge T, Stoer NC, Hverven SK, Nygard M, Trope A, Engesaeter B. Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study. Int J Cancer. 2025 Jul 15;157(2):251-259. doi: 10.1002/ijc.35359. Epub 2025 Feb 8.
- Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024 Aug 3;404(10451):435-444. doi: 10.1016/S0140-6736(24)01097-3.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Pathological Conditions, Signs and Symptoms
- Papillomavirus Infections
Other Study ID Numbers
Other Study ID Numbers
- IPUHPV&CxCa
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD will be derived from the Swedish National Cervical Screening Registry and the Swedish National Quality Register for Gynaecological Cancers. Data from these two registries can be shared upon application, provided that ethical approval is obtained.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.